We’re excited to share our recent work developing a nucleic acid sequence-based amplification pathogen diagnostic for SARS-CoV-2, with 20-200 aM sensitivity. We also develop an explanatory model to gain mechanistic insight into reaction performance. Congratulations to Katie, Dr. Kate Dray, and our wonderful collaborators in the Lucks, Jewett, and Mangan groups. Check out the preprint here!
New preprint: Developing, characterizing and modeling CRISPR-based point-of-use pathogen diagnostics
Bookmark the permalink.